Farmak, the leader in the domestic pharmaceutical market, has expanded the Lamicon antifungal line with a new drug product, Lamicon Dermgel. The new drug is produced in the form of a gel (15 g).
Lamicon Dermgel is an antifungal agent in the form of a gel with a broad spectrum of action and a short course of treatment. It helps to eliminate one of the major symptoms of fungal skin infection – itching.
The drug is recommended for the treatment of skin infections caused by dermatophytes (tinea corporis, tinea cruris, tinea pedis) and tinea versicolor.
The main feature of the new drug is its cooling effect and antipruritic action.
Now the Lamicon antifungal portfolio has three dosage forms for topical use: Lamicon cream, Lamicon spray, Lamicon Dermgel, and also Lamicon in tablet form.
Farmak, as a member of the European Generic Medicines Association (EGA) – Medicines for Europe – and the Association of “Manufacturers of Drugs of Ukraine” (the AMDU), advocates for the creation of a coordination group at the Office of the President of Ukraine to prevent a shortage of medicines in Ukraine during the pandemic. […]
The pharmaceutical company JSC “Farmak” considers the possibility of launching the manufacture of products, in particular, diagnostic test kits, to combat coronavirus spread. “Now we analyse the possibility of arranging the release of supportive care products, disinfectants and antiseptics, diagnostic test kits, protective medical products, including masks, ...
Farmak reinvests 95% of its profits in the development. “We have never paid more than 5% of our profits as dividends. We have reinvested everything in the development. Due to this, Farmak’s capitalization can be estimated at $850 million to $1 billion today. If I sell the shares that I hold, I will earn a […]